Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Sees Oncology Access Programs Key To Growth

This article was originally published in PharmAsia News

Executive Summary

Against a backdrop of increasing payer scrutiny over the high price tags of new cancer treatments, Roche is looking at two main strategies to ensure access to its therapies in the sector, covering both developed countries and emerging markets.

You may also be interested in...



Where Is The Reward? New Drug Developers See Red In China

A new report on China’s pharma innovation ecosystem paints a grim picture of negative market returns for many novel drugs despite shortened review timelines and government calls to encourage innovation.

China Preps For First COVID Vaccine Roll-Outs

Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers. 

China Poised To Conditionally Approve First COVID Vaccine

The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel